Kimia Biosciences Reports Declining Financial Results Amid Rising Interest Costs in June 2025

Kimia Biosciences, a microcap player in the Pharmaceuticals & Biotechnology sector, has reported its financial results for the quarter ending June 2025. The results indicate a notable shift in the company's financial landscape, with a revision in its score reflecting recent performance metrics. The net sales for the quarter stood at Rs 23.58 crore, which represents a significant decline compared to the average net sales of Rs 29.73 crore over the previous four quarters. This downward trend is echoed in the profit before tax less other income (PBT), which recorded a figure of Rs -0.16 crore, marking a stark contrast to the average PBT of Rs 3.08 crore from prior quarters. Additionally, the profit after tax (PAT) was reported at Rs 0.60 crore, a substantial reduction from the average PAT of Rs 2.40 crore. The company also faced challenges with rising interest costs, which reached Rs 1.75 crore, the highest in the last five quarters. This increase in interest expenses, coupled with a declining operating profit margin of 10.73%, suggests a deterioration in the company's operational efficiency. Furthermore, the earnings per share (EPS) fell to Rs 0.13, indicating a reduction in profitability for shareholders. Overall, Kimia Biosciences is navigating a challenging financial environment, as reflected in the recent evaluation changes. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.